This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Charles Marwick

JAMA. 1999;281:1366-1367.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Bethesda, Md—A committee of the Institute of Medicine (IOM) has developed a useful crystal ball for policymakers who have to decide priorities for developing new vaccines, given the available resources. As a way of thinking about different types of vaccines, both preventive and therapeutic, the group estimated the costs and benefits of developing 26 vaccines for managing diseases of domestic importance that were deemed feasible to develop during the next 20 years.

Kathleen R. Stratton, PhD, gave a brief prepublication summary of the report, Vaccines for the 21st Century: A Tool for Decision Making, at the second annual conference on vaccine research held here by the National Foundation for Infectious Diseases. Stratton directs IOM's Division of Health Promotion and Disease Prevention and served as project officer during the report's preparation. Robert Lawrence, MD, dean of the School of Hygiene and Public Health at Johns Hopkins University . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?